July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Future therapy: gene editing
Author Affiliations & Notes
  • Albert Jun
    Ophthal-Woods 376, Johns Hopkins Wilmer Eye Inst, Baltimore, Maryland, United States
  • Footnotes
    Commercial Relationships   Albert Jun, Hunterian Medicine (F), Hunterian Medicine (I), Hunterian Medicine (C)
  • Footnotes
    Support  NIH-EY026238
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 3918. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Albert Jun; Future therapy: gene editing. Invest. Ophthalmol. Vis. Sci. 2018;59(9):3918.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Presentation Description : Genome editing with CRISPR-Cas9 has received much recent attention in biology and medicine. Our laboratory has been studying approaches using CRISPR-Cas9 to potentially treat Fuchs endothelial corneal dystrophy caused by trinucleotide repeat expansions in the TCF4 gene. Efficiency and accuracy of genome editing to remove the trinucleotide repeat region in the TCF4 gene will be presented.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.